1. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding
- Author
-
Mason S, Lu Ls, Boyd Rs, P J Adam, A C Stamps, Graham Steers, K C Gatter, Leach Bi, Stockwin L, Francesco Pezzella, G C Fletcher, J A Loader, Jonathan Alexander Terrett, and Adrian L. Harris
- Subjects
Proteomics ,Cancer Research ,Pathology ,medicine.medical_specialty ,Cell ,Antibodies ,Antigen-Antibody Reactions ,renal cell carcinoma (RCC) ,antibody ,Cell Line, Tumor ,medicine ,Humans ,Receptor ,Molecular Diagnostics ,Carcinoma, Renal Cell ,CD70 ,biology ,Reverse Transcriptase Polymerase Chain Reaction ,Gene Expression Profiling ,Immunohistochemistry ,Kidney Neoplasms ,Gene Expression Regulation, Neoplastic ,Cell killing ,medicine.anatomical_structure ,Oncology ,Cell culture ,biology.protein ,Cancer research ,internalisation ,Antibody ,Clear cell ,CD27 Ligand ,Protein Binding - Abstract
In order to identify potential markers of renal cancer, the plasma membrane protein content of renal cell carcinoma (RCC)-derived cell lines was annotated using a proteomics process. One unusual protein identified at high levels in A498 and 786-O cells was CD70 (TNFSF7), a type II transmembrane receptor normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types demonstrated strong CD70 staining in RCC tissues. Metastatic tissues from eight of 11 patients with clear cell RCC were positive for CD70 expression. Immunocytochemical analysis demonstrated that binding of an anti-CD70 antibody to CD70 endogenously expressed on the surface of A498 and 786-O cell lines resulted in the rapid internalisation of the antibody-receptor complex. Coincubation of the internalising anti-CD70 antibody with a saporin-conjugated secondary antibody before addition to A498 cells resulted in 50% cell killing. These data indicate that CD70 represents a potential target antigen for toxin-conjugated therapeutic antibody treatment of RCC.
- Published
- 2006